Motley Fool Wealth Management LLC Has $19.66 Million Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN

Motley Fool Wealth Management LLC cut its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 20.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 330,853 shares of the biotechnology company’s stock after selling 85,023 shares during the period. BioMarin Pharmaceutical accounts for about 1.5% of Motley Fool Wealth Management LLC’s investment portfolio, making the stock its 16th biggest holding. Motley Fool Wealth Management LLC owned 0.17% of BioMarin Pharmaceutical worth $19,663,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. Northwestern Mutual Investment Management Company LLC boosted its position in BioMarin Pharmaceutical by 0.4% during the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 42,982 shares of the biotechnology company’s stock valued at $2,554,000 after purchasing an additional 183 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in BioMarin Pharmaceutical by 7.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,741 shares of the biotechnology company’s stock valued at $163,000 after purchasing an additional 195 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in BioMarin Pharmaceutical by 3.4% during the third quarter. EverSource Wealth Advisors LLC now owns 7,151 shares of the biotechnology company’s stock valued at $387,000 after purchasing an additional 235 shares during the last quarter. Davis Investment Partners LLC boosted its position in BioMarin Pharmaceutical by 3.1% during the fourth quarter. Davis Investment Partners LLC now owns 8,031 shares of the biotechnology company’s stock valued at $477,000 after purchasing an additional 243 shares during the last quarter. Finally, Parallel Advisors LLC boosted its position in BioMarin Pharmaceutical by 62.2% during the third quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 295 shares during the last quarter. 98.71% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Barclays increased their price target on BioMarin Pharmaceutical from $80.00 to $105.00 and gave the company an “overweight” rating in a research report on Tuesday, March 3rd. Weiss Ratings upgraded BioMarin Pharmaceutical from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, May 29th. Royal Bank Of Canada restated a “sector perform” rating and issued a $66.00 price objective on shares of BioMarin Pharmaceutical in a research note on Tuesday, May 5th. Jefferies Financial Group restated a “buy” rating and issued a $103.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, March 12th. Finally, Canaccord Genuity Group dropped their price objective on BioMarin Pharmaceutical from $116.00 to $111.00 and set a “buy” rating on the stock in a research note on Friday, May 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat, BioMarin Pharmaceutical currently has a consensus rating of “Moderate Buy” and a consensus price target of $88.67.

BioMarin Pharmaceutical Price Performance

NASDAQ:BMRN opened at $57.91 on Wednesday. The firm has a market capitalization of $11.19 billion, a price-to-earnings ratio of 42.27, a P/E/G ratio of 0.43 and a beta of 0.25. The company has a quick ratio of 4.20, a current ratio of 5.81 and a debt-to-equity ratio of 0.23. BioMarin Pharmaceutical Inc. has a 12-month low of $49.26 and a 12-month high of $66.28. The stock’s 50 day moving average price is $54.37 and its two-hundred day moving average price is $56.40.

Insider Buying and Selling at BioMarin Pharmaceutical

In other news, EVP Gregory R. Friberg sold 3,281 shares of the stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $53.85, for a total transaction of $176,681.85. Following the transaction, the executive vice president owned 51,818 shares in the company, valued at approximately $2,790,399.30. This trade represents a 5.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.85% of the company’s stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.